Intellia Halts Major Trial Following Severe Liver Incident, Shares Plummet
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Source: Benzinga
Trial Pause: Intellia Therapeutics has paused patient dosing and screening in its Phase 3 MAGNITUDE trials for its CRISPR therapy, nexiguran ziclumeran (nex-z), due to a serious liver-related adverse event in a participant.
Patient Safety Commitment: The company is working with regulators and medical experts to assess the incident, emphasizing its commitment to patient safety and planning to safely resume enrollment.
Promising Phase 1 Results: Long-term follow-up data from a Phase 1 trial showed significant reductions in transthyretin protein levels and improvements in neuropathy scores among patients treated with nex-z.
Market Impact: Following the announcement of the trial pause, Intellia's shares fell by over 43%, reflecting investor concerns about the implications for the ongoing MAGNITUDE trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 56.380
Low
50.00
Averages
78.89
High
105.00
Current: 56.380
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choices in Gene Editing Technology
- CRISPR Therapeutics Status: CRISPR Therapeutics relies on Vertex Pharmaceuticals for the commercialization of its CASGEVY product, generating only $3.5 million in revenue for fiscal 2025 while incurring a net loss of $581.6 million, highlighting its high dependency on a single partner and increasing investment risk.
- Editas Medicine Growth: Editas Medicine reported $40.5 million in revenue for fiscal 2025, a 25.4% increase year-over-year, despite facing a net loss of $160.1 million and a negative net margin of 395%, indicating significant cost challenges in the gene therapy sector.
- Risk Comparison: CRISPR Therapeutics faces legal challenges and dependency on Vertex, which may affect revenue timing, while Editas relies on a single preclinical candidate, meaning any setbacks in early testing could severely impact its valuation.
- Valuation Differences: CRISPR's forward P/E ratio stands at 23.4x, while Editas has a P/S ratio of 8x, indicating that Editas's stock valuation is relatively reasonable, although its balance sheet is weaker with cash of only $146.6 million, posing dilution risks for shareholders.
See More
Investment Choices in Gene Editing Technology
- Dependency of CRISPR Therapeutics: CRISPR Therapeutics relies heavily on Vertex Pharmaceuticals for the commercialization of CASGEVY, reporting a net loss of $581.6 million in fiscal 2025, which highlights the risks associated with its concentrated revenue stream, while its debt-to-equity ratio stands at 0.2, indicating low leverage.
- Growth Potential of Editas Medicine: Editas Medicine achieved revenue of $40.5 million in fiscal 2025, reflecting a 25.4% year-over-year growth, despite a net loss of $160.1 million and a net margin of negative 395%, underscoring the high costs associated with developing genomic therapies and the potential market opportunities.
- Risk Comparison: CRISPR Therapeutics faces legal challenges, including a patent infringement lawsuit, and its dependency on Vertex limits its revenue control, while Editas relies on third-party providers due to a lack of internal manufacturing, increasing the risk of supply chain disruptions.
- Valuation Differences: CRISPR Therapeutics has a forward P/E ratio of 23.4x, while Editas has a P/S ratio of 8190x, indicating that Editas's stock valuation is relatively reasonable, even though CRISPR has a lead in FDA approvals, potentially giving it a market advantage.
See More
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam
- CRISPR Therapeutics Progress: In 2023, CRISPR Therapeutics received approval for Casgevy, a treatment for sickle cell disease and transfusion-dependent beta-thalassemia, which, despite currently low revenue, is expected to see significant commercial growth in the coming years.
- Pipeline Advantage: CRISPR Therapeutics boasts a deeper pipeline, including CTX310 aimed at lowering LDL cholesterol, offering a potential one-time treatment option that could enhance its market competitiveness and stock price.
- Beam Therapeutics Innovation: Beam Therapeutics focuses on base editing technology and, while lacking marketed products, has shown strong results with its clinical candidate Risto-cel, with plans to submit a regulatory application by year-end, potentially driving stock price increases.
- Financial Comparison: As of the end of Q1, CRISPR Therapeutics held $2.4 billion in cash and equivalents compared to Beam Therapeutics' $1.2 billion, providing CRISPR with greater resilience against clinical trial setbacks, making it a more attractive investment choice.
See More
Analysis of Gene Editing Industry Prospects
- CRISPR Breakthrough: CRISPR Therapeutics received approval for Casgevy in 2023, a treatment for sickle cell disease and transfusion-dependent beta-thalassemia, which, despite currently low revenue, is expected to see significant commercial growth in the coming years.
- Pipeline Advantage: The company's CTX310 is being developed to lower LDL cholesterol as a potential one-time treatment option, which could provide a more convenient choice in cardiovascular disease management, thereby enhancing its competitive position in the market.
- Beam Innovation: Beam Therapeutics focuses on base editing technology and, while it currently has no products on the market, its Risto-cel candidate has shown strong results in clinical trials, with plans to submit a regulatory application by year-end, potentially driving its stock price higher.
- Financial Comparison: As of the end of Q1, CRISPR Therapeutics had $2.4 billion in cash and marketable securities compared to Beam Therapeutics' $1.2 billion, indicating stronger financial stability that provides better resilience against clinical trial setbacks.
See More
2026 Investment Strategy: Focus on Quality Stocks
- Roku Market Share Growth: Roku's share of the North American connected TV market has reached 36%, nearly double that of Amazon, and despite stagnation in the streaming industry, Roku's platform revenue grew by 28% year-over-year, demonstrating its strong profitability in digital entertainment sales.
- ServiceNow Long-Term Growth Potential: With a market cap of $107 billion, ServiceNow is projected to grow its revenue from $13.3 billion in 2025 to $29.5 billion by 2030, reflecting an annualized growth rate of nearly 25%, indicating its sustained leadership in the workflow automation sector.
- CRISPR Therapeutics Market Outlook: CRISPR Therapeutics' gene therapy Casgevy has received FDA approval, with sales expected to reach $40 million this year and potentially double next year, highlighting its significant potential in the gene editing market despite high costs and complex treatment processes.
- Investor Sentiment Shift: The volatile start to 2026 has left many investors uncertain; however, maintaining a focus on quality stocks as a long-term investment strategy remains the best approach to avoid missteps caused by short-term market fluctuations.
See More
CRISPR Therapeutics Shows Promising Upside Potential
- Strong Stock Performance: CRISPR Therapeutics' shares have surged 56% over the past year, significantly outperforming the S&P 500's 30% gain, indicating robust market confidence in its growth prospects.
- Optimistic Analyst Targets: According to Yahoo! Finance, CRISPR's average price target is $82.55, suggesting nearly 51% upside from current levels, while Piper Sandler's analyst has set a target of $110, indicating the stock could potentially double in the next 12 months.
- Catalysts from Clinical Trials: The ongoing development of the anticoagulant CTX611 could yield crucial clinical trial data in the coming months, targeting a $20 billion market, and positive results could significantly boost the stock price.
- Market Expansion Potential: The Casgevy drug, developed in collaboration with Vertex Pharmaceuticals, has yet to generate significant sales despite its 2023 approval due to its complex administration and high cost; however, the recent request for approval for children aged 5 to 11 could greatly expand its market potential, with annual revenues expected to exceed $1 billion in the coming years.
See More
Investment Choices in Gene Editing Technology
- CRISPR Therapeutics Status: CRISPR Therapeutics relies on Vertex Pharmaceuticals for the commercialization of its CASGEVY product, generating only $3.5 million in revenue for fiscal 2025 while incurring a net loss of $581.6 million, highlighting its high dependency on a single partner and increasing investment risk.
- Editas Medicine Growth: Editas Medicine reported $40.5 million in revenue for fiscal 2025, a 25.4% increase year-over-year, despite facing a net loss of $160.1 million and a negative net margin of 395%, indicating significant cost challenges in the gene therapy sector.
- Risk Comparison: CRISPR Therapeutics faces legal challenges and dependency on Vertex, which may affect revenue timing, while Editas relies on a single preclinical candidate, meaning any setbacks in early testing could severely impact its valuation.
- Valuation Differences: CRISPR's forward P/E ratio stands at 23.4x, while Editas has a P/S ratio of 8x, indicating that Editas's stock valuation is relatively reasonable, although its balance sheet is weaker with cash of only $146.6 million, posing dilution risks for shareholders.
See More
Investment Choices in Gene Editing Technology
- Dependency of CRISPR Therapeutics: CRISPR Therapeutics relies heavily on Vertex Pharmaceuticals for the commercialization of CASGEVY, reporting a net loss of $581.6 million in fiscal 2025, which highlights the risks associated with its concentrated revenue stream, while its debt-to-equity ratio stands at 0.2, indicating low leverage.
- Growth Potential of Editas Medicine: Editas Medicine achieved revenue of $40.5 million in fiscal 2025, reflecting a 25.4% year-over-year growth, despite a net loss of $160.1 million and a net margin of negative 395%, underscoring the high costs associated with developing genomic therapies and the potential market opportunities.
- Risk Comparison: CRISPR Therapeutics faces legal challenges, including a patent infringement lawsuit, and its dependency on Vertex limits its revenue control, while Editas relies on third-party providers due to a lack of internal manufacturing, increasing the risk of supply chain disruptions.
- Valuation Differences: CRISPR Therapeutics has a forward P/E ratio of 23.4x, while Editas has a P/S ratio of 8190x, indicating that Editas's stock valuation is relatively reasonable, even though CRISPR has a lead in FDA approvals, potentially giving it a market advantage.
See More
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam
- CRISPR Therapeutics Progress: In 2023, CRISPR Therapeutics received approval for Casgevy, a treatment for sickle cell disease and transfusion-dependent beta-thalassemia, which, despite currently low revenue, is expected to see significant commercial growth in the coming years.
- Pipeline Advantage: CRISPR Therapeutics boasts a deeper pipeline, including CTX310 aimed at lowering LDL cholesterol, offering a potential one-time treatment option that could enhance its market competitiveness and stock price.
- Beam Therapeutics Innovation: Beam Therapeutics focuses on base editing technology and, while lacking marketed products, has shown strong results with its clinical candidate Risto-cel, with plans to submit a regulatory application by year-end, potentially driving stock price increases.
- Financial Comparison: As of the end of Q1, CRISPR Therapeutics held $2.4 billion in cash and equivalents compared to Beam Therapeutics' $1.2 billion, providing CRISPR with greater resilience against clinical trial setbacks, making it a more attractive investment choice.
See More
Analysis of Gene Editing Industry Prospects
- CRISPR Breakthrough: CRISPR Therapeutics received approval for Casgevy in 2023, a treatment for sickle cell disease and transfusion-dependent beta-thalassemia, which, despite currently low revenue, is expected to see significant commercial growth in the coming years.
- Pipeline Advantage: The company's CTX310 is being developed to lower LDL cholesterol as a potential one-time treatment option, which could provide a more convenient choice in cardiovascular disease management, thereby enhancing its competitive position in the market.
- Beam Innovation: Beam Therapeutics focuses on base editing technology and, while it currently has no products on the market, its Risto-cel candidate has shown strong results in clinical trials, with plans to submit a regulatory application by year-end, potentially driving its stock price higher.
- Financial Comparison: As of the end of Q1, CRISPR Therapeutics had $2.4 billion in cash and marketable securities compared to Beam Therapeutics' $1.2 billion, indicating stronger financial stability that provides better resilience against clinical trial setbacks.
See More
2026 Investment Strategy: Focus on Quality Stocks
- Roku Market Share Growth: Roku's share of the North American connected TV market has reached 36%, nearly double that of Amazon, and despite stagnation in the streaming industry, Roku's platform revenue grew by 28% year-over-year, demonstrating its strong profitability in digital entertainment sales.
- ServiceNow Long-Term Growth Potential: With a market cap of $107 billion, ServiceNow is projected to grow its revenue from $13.3 billion in 2025 to $29.5 billion by 2030, reflecting an annualized growth rate of nearly 25%, indicating its sustained leadership in the workflow automation sector.
- CRISPR Therapeutics Market Outlook: CRISPR Therapeutics' gene therapy Casgevy has received FDA approval, with sales expected to reach $40 million this year and potentially double next year, highlighting its significant potential in the gene editing market despite high costs and complex treatment processes.
- Investor Sentiment Shift: The volatile start to 2026 has left many investors uncertain; however, maintaining a focus on quality stocks as a long-term investment strategy remains the best approach to avoid missteps caused by short-term market fluctuations.
See More
CRISPR Therapeutics Shows Promising Upside Potential
- Strong Stock Performance: CRISPR Therapeutics' shares have surged 56% over the past year, significantly outperforming the S&P 500's 30% gain, indicating robust market confidence in its growth prospects.
- Optimistic Analyst Targets: According to Yahoo! Finance, CRISPR's average price target is $82.55, suggesting nearly 51% upside from current levels, while Piper Sandler's analyst has set a target of $110, indicating the stock could potentially double in the next 12 months.
- Catalysts from Clinical Trials: The ongoing development of the anticoagulant CTX611 could yield crucial clinical trial data in the coming months, targeting a $20 billion market, and positive results could significantly boost the stock price.
- Market Expansion Potential: The Casgevy drug, developed in collaboration with Vertex Pharmaceuticals, has yet to generate significant sales despite its 2023 approval due to its complex administration and high cost; however, the recent request for approval for children aged 5 to 11 could greatly expand its market potential, with annual revenues expected to exceed $1 billion in the coming years.
See More
